Licensing · Southeast Asia · Announced 10 Nov 2025

Bio-Thera Solutions → Dr. Reddy's Laboratories

Bio-Thera granted Dr. Reddy's an exclusive licence to register and commercialise BAT2306, its secukinumab (Cosentyx) biosimilar, in nine Southeast Asian markets; Bio-Thera will develop, manufacture and supply.

Parties: Bio-Thera Solutions (China) → Dr. Reddy's Laboratories (India)

Deal type
Licensing
Value
Undisclosed
Territory
Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Thailand, Vietnam
Asset
secukinumab
Announced
10 Nov 2025

Our analysis

Why this matters

On 10 November 2025 Bio-Thera Solutions announced an exclusive commercialisation and licence agreement with Dr. Reddy's Laboratories for BAT2306, its biosimilar to Novartis's Cosentyx (secukinumab). Dr. Reddy's is responsible for regulatory approvals and commercialisation in Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Thailand and Vietnam. Bio-Thera develops, manufactures and supplies the product. Financial terms were not disclosed.

In October 2026 BAT2306 (Youzhuomei) became, by Bio-Thera's account, the first secukinumab biosimilar approved by any major regulator, with China's NMPA clearing it for psoriasis, ankylosing spondylitis and psoriatic arthritis. That approval strengthens the reference dossier partners can use in Southeast Asia.

The full analysis is free to read with a work email on this page.

Source: Pearce IP

More deals involving Bio-Thera Solutions or Dr. Reddy's Laboratories

Latest deals

All Southeast Asia deals → · All licensing deals → · Browse all emerging-market pharma deals →